Search

Your search keyword '"Nijman, Hans W."' showing total 622 results

Search Constraints

Start Over You searched for: Author "Nijman, Hans W." Remove constraint Author: "Nijman, Hans W."
622 results on '"Nijman, Hans W."'

Search Results

1. Ovarian cancer

3. Automated causal inference in application to randomized controlled clinical trials

4. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials

5. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry

8. Diagnostic accuracy of MRI, CT, and [18F]FDG-PET-CT in detecting lymph node metastases in clinically early-stage cervical cancer — a nationwide Dutch cohort study

11. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial

12. A federated approach to identify women with early-stage cervical cancer at low risk of lymph node metastases

13. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts

14. Prediction of recurrence risk in endometrial cancer with multimodal deep learning

15. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients

18. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy

19. Age-Related Differences in Patient Preferences for Adjuvant Chemotherapy for High-Risk Endometrial Cancer

21. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making

22. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial

25. Ovarian cancer

28. HECTOR: multimodal deep learning predicts recurrence risk in endometrial cancer.

29. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, -2 and -3 trials

31. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

34. Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative

35. ImmunoPET provides a novel way to visualize the CD103+ tissue-resident memory T cell to predict the response of immune checkpoint inhibitors.

36. Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors

38. Development of 89Zr and 68Ga-anti-CD103 Fab-fragments for PET imaging to non-invasively assess cancer reactive T cell infiltration--- Fab-based CD103 immunoPET

39. Abstract 5695: Deep learning risk prediction model of distant recurrence from H&E endometrial cancer slides

40. Data from Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer

41. Data from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer

42. Supplementary Table 7 from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer

43. Supplementary Tables 1-6, 8 from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer

44. Supplementary Figures from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer

45. Supplementary Data from Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer

46. Supplementary Methods from Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer

47. Supplementary figure 6 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

48. Supplementary figure 1 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

49. Supplementary Table S5 from Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts

50. Supplementary figure 4 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

Catalog

Books, media, physical & digital resources